Cancer Drugs

Natural Cancer Supplement: Cell Forte with IP-6 and Inositol by Enzymatic Therapy

Tue, 13 Feb 2007 07:47:09 +0100

Cell Forte with IP-6 is a unique combination of inositol and inositol hexaphosphate (IP-6). Together, inositol and IP-6 create a remarkable increase in natural killer cell activity and enhances natural cellular defenses. Both inositol and IP-6 are found naturally in the cells of the body. However, studies show that by supplementing with Cell Forte, the cells become stronger.

New cancer drugs may save 1,300 lives a year, tests show

Tue, 13 Feb 2007 08:04:35 +0100

An extra 1,300 lives a year could be saved in the UK if all women with breast cancer were given new drugs that deprive the tumour of oxygen, research suggests today.

Presented By

Tue, 13 Feb 2007 08:04:35 +0100

Study finds newer breast cancer drugs save lives

Mon, 12 Feb 2007 04:34:42 +0100

Women who switch from the breast cancer pill tamoxifen to a newer class of drugs called aromatase inhibitors live longer, Italian researchers reported on Monday.

Presented By

Mon, 12 Feb 2007 04:34:42 +0100

Newer cancer drugs may save lives

Mon, 12 Feb 2007 15:39:48 +0100

Women who switch from the breast cancer pill tamoxifen to a newer class of drugs called aromatase inhibitors live longer, Italian researchers reported.

Presented By

Mon, 12 Feb 2007 15:39:48 +0100

51 Utahns pin cancer on drugs

Mon, 12 Feb 2007 07:09:19 +0100

A growing number of Utah women are alleging they developed breast cancer after taking hormone therapy drugs to ease menopause-related problems and to help keep them "feminine forever."Fifty-one women filed lawsuits in 3rd District Court in Salt Lake City in December against drug manufacturers Wyeth Pharmaceuticals and Pfizer Inc., joining at least 24 other Utah women who previously sued the ...

Presented By

Mon, 12 Feb 2007 07:09:19 +0100

Newer Drugs Beat Tamoxifen for Breast Cancer Survival

Mon, 12 Feb 2007 16:01:28 +0100

MONDAY, Feb. 12 (HealthDay News) - Postmenopausal breast cancer patients who switch from tamoxifen therapy to another type of drug, called an aromatase inhibitor, may gain a significant boost in survival, Italian research shows.

Presented By

Mon, 12 Feb 2007 16:01:28 +0100

Newer Drugs Beat Tamoxifen for Breast Cancer Survival

Mon, 12 Feb 2007 21:49:52 +0100

By Alan Mozes ,HealthDay Reporter MONDAY, Feb. 12 (HealthDay News) - Postmenopausal breast cancer patients who switch from tamoxifen therapy to another type of...

Presented By

Mon, 12 Feb 2007 21:49:52 +0100

Switching to newer breast cancer drugs boosts survival

Mon, 12 Feb 2007 07:08:28 +0100

ATLANTAFeb. 12, 2007Switching from tamoxifen to a newer anti-estrogen treatment within three years after breast cancer surgery significantly improves survival rates, according to a new study.

Presented By

Mon, 12 Feb 2007 07:08:28 +0100

Geron Gets OK to Study Cancer Vaccine

Mon, 12 Feb 2007 20:34:06 +0100

Geron Corp., which develops drugs and vaccines using stem cells, on Monday said it received government approval to begin enrolling patients in clinical trials of an experimental cancer vaccine.

Presented By

Mon, 12 Feb 2007 20:34:06 +0100

Newer Drugs Beat Tamoxifen for Breast Cancer Survival

Mon, 12 Feb 2007 21:46:41 +0100

Aromatase inhibitors may also be safer over the long term, study suggests.

Presented By

Mon, 12 Feb 2007 21:46:41 +0100

Progress Analysis of Top 7 Cancer Indications, Including Players, Drugs, Clinical Progress and Pitfalls

Research and Markets ( httpwww.researchandmarkets.com/reports/c50146) has announced the addition of Top 7 Cancer Indications - Therapeuticand amp; Competitive Insights to their offering. With our 750 page report entitled "Top 7 Cancer Indications - Therapeuticand amp; Competitive Insights" we present ...

Presented By

Many Stop Taking Breast Cancer Drugs Side Effects Blamed; Survival Could Be at Risk

Drugs developed in the past decade can dramatically cut the chances that breast cancer will return. But many women stop taking the drugs before the end of the recommended five-year course of therapy, often because of the side effects. The poor compliance worries doctors, who say women could be ...

Presented By

Antisense Oligonucleotides Have Been in Clinical Trials for Cancer for Some Time Now - Drug Delivery in Cancer - Technologies, Markets and Companies Report 2007

Research and Markets ( httpwww.researchandmarkets.com/reports/c1346) has announced the addition of 'Drug Delivery in Cancer - Technologies, Markets and Companies Report' to their offering. Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are ...

Presented By

Callisto's Cancer Drug Atiprimod to Be Presented at the Annual Meeting of American Association of Cancer Research.

NEW YORK, January 25 /PRNewswire/ - Callisto Pharmaceuticals, Inc. , a biopharmaceutical company primarily focused on the development of drugs to treat cancer and other major health threats, today announced acceptance of an abstract on Atiprimod, the Company's ...

Presented By

Callisto's Cancer Drug Atiprimod to Be Presented at the Annual Meeting of American Association of Cancer Research

NEW YORK, Jan. 25 /PRNewswire-FirstCall/ - Callisto Pharmaceuticals, Inc. , a biopharmaceutical company primarily focused on the development of drugs to treat cancer and other major health threats, today announced acceptance of an abstract on Atiprimod, the Company's ...

Presented By

Callisto's Cancer Drug Atiprimod to Be Presented at Scientific Conference on Cancer Drugs and Angiogenesis.

NEW YORK, Jan. 24 /PRNewswire-FirstCall/ - Callisto Pharmaceuticals, Inc. , a biopharmaceutical company primarily focused on the development of drugs to treat cancer and other major health threats, today announced that Dr. Kunwar Shailubhai will be giving an invited presentation on ...

Presented By

Callisto's Cancer Drug Atiprimod to Be Presented at Scientific Conference on Cancer Drugs and Angiogenesis

Presented By

Cancer drugs: weighing the risks and benefits.

Few deliberations have greater bearing on human health than when the Food and Drug Administration weighs the risks and benefits of drugs designed to treat life-threatening diseases, such as cancer. FDA physicians who specialize in treating cancer , chemists, statisticians, ...

Presented By

Targeted Cancer Drugs May Work by Disrupting Balance of Cellular Signals; Study Supports New Model of Drug Action That May Explain Problems, Suggest New Approaches.

Byline: Massachusetts General Hospital BOSTON, Nov. 13- Targeted cancer therapy drugs like Gleevecand Tarceva , which destroy tumors by interfering with specific proteins or protein pathways, may disrupt the balance between critical cellular signals in a ...

'Let cancer patients pay to top-up NHS drugs'.

Byline: JENNY HOPE HEALTH Service patients should be able to pay to upgrade their cancer drugs, a medical expert has said. Professor Karol Sikora, former head of the World Health Organisation, called for a 'top-up' payment system to improve care for those prepared to spend more in exchange for a ...

Fed: Sufferers welcome breast cancer drugs being added to PBS

Fed: Sufferers welcome breast cancer drugs being added to PBS By Jane Bunce CANBERRA, Oct 27 AAP - Breast cancer advocates have hailed the listing of two new drugs onto the Pharmaceutical Benefits Scheme for allowing sufferers to seek the best treatment regardless of cost. The drugs are ...

Presented By

Community Oncology Alliance Refutes NBC Nightly News Story 'Cancer Docs Profit from Chemotherapy Drugs'.

WASHINGTON, Sept. 22 /PRNewswire/ - The Community Oncology Allianceregistered outrage in a letter to Steve Capus, President, NBC News, regarding the story appearing on NBC Nightly News, September 21, 2006, entitled, 'Cancer Docs Profit from Chemotherapy Drugs' reported by Rehema Ellis. ...

Cancer care is improving; National Cancer Director announces better access to NICE approved cancer drugs.

M2 PRESSWIRE-20 September 2006-UK Government: Cancer care is improving; National Cancer Director announces better access to NICE approved cancer drugs1994-2006 M2 COMMUNICATIONS LTD RDATE:20092006 The Cancer Plan is improving care for cancer patients was the message from National Cancer Director ...

Prostate Cancer Drugs May Pose Danger; Study Finds Common Therapy Might Increase Risks of Heart Disease, Diabetes

Drugs commonly used to treat prostate cancer may increase the risk of heart disease and diabetes, indicating the treatments should be used more judiciously, researchers reported yesterday. The findings apply to thousands of American men because prostate cancer is the second-most-common cancer in ...

Study Uncovers Mechanism of Drug Resistance in Form of Lung Cancer.

Byline: Dana-Farber Cancer Institute BOSTON, Sept. 6- Dana-Farber Cancer Institute researchers and their colleagues have demonstrated that a genetic error so scarce it can't be detected with some standard screening equipment is often responsible for the loss of effectiveness of ...

MedImmune and Infinity Pharmaceuticals Announce Cancer Drug Development and Worldwide Commercialization Agreement.

- Alliance to Focus on Novel, Targeted Small Molecule Cancer Therapeutics in Two Key Programs - GAITHERSBURG, Md. and CAMBRIDGE, Mass., Aug. 28 /PRNewswire-FirstCall/ - MedImmune, Inc. and Infinity Pharmaceuticals, Inc. today announced that they have entered into an agreement to jointly develop ...

FOCUS: Government needs a new Cancer Plan now ; Today the Government will be warned it must review its NHS Cancer Plan to tackle the future pressures of an ageing population and expensive new drugs. F

Health Reporter Emma Brady Birmingham Post 08-24-2006 FOCUS: Government needs a new Cancer Plan now ; Today the Government will be warned it must review its NHS Cancer Plan to tackle the future pressures of an ageing population and expensive new drugs. Following funding rows over drugs such as ...

FOCUS: Government needs a new Cancer Plan now; Today the Government will be warned it must review its NHS Cancer Plan to tackle the future pressures of an ageing population and expensive new drugs. Following funding rows over drugs such as Herceptin, Avastin and Erbitux, Health Reporter Emma Brady looks at whether NHS offers can cope with the influx of new treatments.

Byline: Health Reporter Emma Brady Today, more and more people are living with cancer as a result of improved diagnostics, shortened waiting times, and a host of new drugs and treatments. But unfortunately this all comes at a price - and it's not cheap. As the ageing population grows and ...

Targeted therapies set to top cancer drug sales charts.

M2 PRESSWIRE-17 August 2006-DATAMONITOR: Targeted therapies set to top cancer drug sales charts1994-2006 M2 COMMUNICATIONS LTD RDATE:18082006 London Friday August 18 2006- A fundamental change in the treatment of cancer is underway, with the cytotoxic drugs used in chemotherapy regimes set to ...